Annovis Bio, Inc. (ANVS) is a publicly traded Healthcare sector company. As of October 20, 2026, ANVS trades at $0.98 with a market cap of $42.40M and a P/E ratio of -0.84. ANVS moved +2.08% today. Year to date, ANVS is -73.70%; over the trailing twelve months it is -51.52%. Its 52-week range spans $0.95 to $5.50. Analyst consensus is strong buy with an average price target of $10.67. Rallies surfaces ANVS's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
3 analysts cover ANVS: 0 strong buy, 3 buy, 0 hold, 0 sell, and 0 strong sell. The consensus rating is strong buy. The average price target is $10.67.
| Metric | Value |
|---|---|
| Price | $0.98 |
| Market Cap | $42.40M |
| P/E Ratio | -0.84 |
| EPS | $-1.40 |
| Dividend Yield | 0.00% |
| 52-Week High | $5.50 |
| 52-Week Low | $0.95 |
| Volume | 0 |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $-28.85M |
| Gross Margin | 0.00% |
3 analysts cover ANVS: 0 strong buy, 3 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $10.67.